drugset / Trial / NCT01031186

First Time in Human Study

NCT01031186

Phase 1 Completed 20 enrolled GlaxoSmithKline
RandomizedCrossoverSingle-blindTreatment

Summary

This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers

Timeline

Start
2009-11-23
Primary completion
2010-04-07
Completion
2010-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK356278 Small molecule 0.5 mg
Subject GSK356278 Small molecule 1.5 mg
Subject GSK356278 Small molecule 4 mg
Subject GSK356278 Small molecule 8 mg
Subject GSK356278 Small molecule 16 mg
Subject GSK356278 Small molecule 30 mg
Subject GSK356278 Small molecule 50 mg